By Len Zehr Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that...
Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid addiction, validate the...
By Len Zehr Closely-held KAHR Medical of Israel is seeking to raise* as much as $10-million in the U.S. and Europe to continue development of its dual signaling proteins (DSPs), including KAHR-102, its lead drug...
Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of...
By Len Zehr Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose...
By Len Zehr T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx...
By Len Zehr Axcelon Biopolymers, which plans to go public in the current quarter, has developed a sales and marketing plan with a leading wholesaler and its own sales team to gain maximum market share in Canada for its...
By Len Zehr TransEnterix (NYSE MKT:TRXC) plans to file for FDA approval in mid-year of its SurgiBot robotic platform to enhance minimally invasive laparoscopic surgery through a single surgical incision. “We anticipate...
By Len Zehr As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start...
By Len Zehr As president and CEO of Encision (OTCQB:ECIA), Greg Trudel, who moved into the executive suite in December 2013, has always had a strong interest in energy, dating back to various leadership posts with...